Latest Cannabis Stories
SAN DIEGO, Nov. 15, 2012 /PRNewswire/ -- CanChew BioTechnologies Inc, a portfolio company of Medical Marijuana Inc. (OTC: MJNA), announces that this is the final day to register for the market trial of CanChew gum. Qualifying participants will receive a minimum of a 30-day free trial sample of the CBD-based CanChew gum in exchange for their product feedback. The only cost involved will be a nominal shipping charge of $4.95 for delivery of the product. While the company has been...
SAN DIEGO, Nov. 15, 2012 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), a leading cannabis and hemp industry innovator, today announced its third quarter earnings. The company earned net income of approximately $1.19 million on gross revenues of $3.00 million for the quarter ended Sept 30, 2012. This represents a gross revenue increase of 1500 plus percent quarter-over-quarter when compared to revenue of $198,813 for the quarter ended Sept 30, 2011. Operational and...
The ability of cannabis to produce psychosis has long been an important public health concern. This concern is growing in importance as there is emerging data that cannabis exposure during adolescence may increase the risk of developing schizophrenia, a serious psychotic disorder. Further, with the advent of medical marijuana, a new group of people with uncertain psychosis risk may be exposed to cannabis. For these reasons, it would be valuable if a biological test could be developed that...
Kentucky Initiative Seeks to Pass Laws on the State and Federal Level to Allow Widespread Growth of Industrial Hemp WASHINGTON, Nov. 13, 2012 /PRNewswire-USNewswire/ -- On Nov. 14 at 10:00 a.m. ET, representatives of the nation's leading industrial hemp advocacy group, Vote Hemp, and top-selling natural soap brand Dr. Bronner's Magic Soaps will meet with Kentucky Senator Rand Paul's staff and members of the revived Kentucky Industrial Hemp Commission, led by Kentucky Agriculture...
SAN DIEGO, Nov. 13, 2012 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) has announced the integration and expansion of its PhytoSPHERE subsidiary. This move gives the nation's premier hemp nutraceutical firm full management oversight of its manufacturing and quality assurance processes for all of its existing and emerging products. "MJNA's strategy is really good news for the company, industry, and consumers," said John Malanca, owner of patient-oriented medical marijuana...
SAN DIEGO, Nov. 13, 2012 /PRNewswire/ -- CanChew BioTechnologies Inc, a portfolio company of Medical Marijuana Inc. (OTC: MJNA), announces that this week marks the final three days to register for the market trial of CanChew gum. Qualifying participants will receive a minimum of a 30-day free trial sample of the CBD-based CanChew gum in exchange for their product feedback. The only cost involved will be a nominal shipping charge of $4.95 for delivery of the product. While the...
SEATTLE, Nov. 13, 2012 /PRNewswire/ -- The Association of Medical Marijuana Producers and Processors (AMMP) today announced that it has been restructured as the Evergreen State Cannabis Trade Alliance. The reorganization enables the Alliance to enhance AMMP's existing set of safety standards - designed to ensure that qualifying medical patients have access to the safest cannabis in the United States - for a wider consumer base under Washington State Initiative 502. Marijuana...
COLORADO SPRINGS, Colo., Nov. 13, 2012 /PRNewswire/ -- Cannabis Science Inc., (OTC:CBIS) announced today the appointment of Harvard Law School Graduate Chad S. Johnson, Esq., as a member of the company's Board of Directors and as General Counsel, adding significant expertise to Cannabis Science's management team in business development, legal & regulatory compliance, and for-profit and non-profit partnerships. About Chad S. Johnson, Esq. Mr. Johnson, a native of Emporia,...
COLORADO SPRINGS, Colo., Nov. 12, 2012 /PRNewswire/ -- Cannabis Science, Inc., (CBIS) announces Harvard Medical School releases peer-reviewed study in the Genes & Cancer Journal strongly suggesting that Cannabidiol inhibits growth and induces programmed cell death in Kaposi Sarcoma-associated Herpesvirus-Infected Endothelium. These results from the study at Harvard Medical School support Cannabis Science's approach to the development of CS-TATI-1 to inhibit Kaposi Sarcoma....
COLORADO SPRINGS, Colo., Nov. 9, 2012 /PRNewswire/ -- Cannabis Science Inc., (OTC: CBIS) is pleased to announce an opportunity to directly respond to our investors regarding our corporate developments and preclinical initiatives via a 1(st) Q of 2013 webinar investor call. As we continue to build our team of world-renowned experts to bring CS-S/BCC-1 and CS-TATI-1 through our preclinical investigation and into subsequent human clinical studies to satisfy the FDA regulatory process...
